Novo Nordisk Sues Hims & Hers Over Obesity Treatment, Hims & Hers Shares Plunge 50%
Novo Nordisk filed a patent lawsuit on February 13, 2026, accusing Hims & Hers of infringing its obesity drug intellectual property rights. Hims & Hers shares plunged over 50% on the day, signaling investor concern over potential litigation costs and market exclusivity challenges.
1. Lawsuit Announcement
On February 13, 2026, Novo Nordisk initiated legal action against Hims & Hers, alleging that the telehealth company’s recently launched obesity treatment infringes on Novo Nordisk’s patents for weight-loss medications. The complaint seeks to protect Novo Nordisk’s market exclusivity and asserts that Hims & Hers’ product contains drug formulations covered by its intellectual property portfolio.
2. Market Reaction and Implications
Hims & Hers’ stock collapsed by more than 50% immediately following the lawsuit filing, reflecting investor concerns about costly litigation and delayed product rollouts. The suit underscores the competitive dynamics in the obesity drug market and may deter similar entrants while bolstering Novo Nordisk’s pricing power and patent defenses.